Halozyme Therapeutics (NEO:HALO) Stock Price Up 0.1%

Shares of Halozyme Therapeutics, Inc. (NEO:HALO) rose 0.1% during trading on Thursday . The company traded as high as C$36.39 and last traded at C$35.51. Approximately 1,016,476 shares were traded during mid-day trading, an increase of 13% from the average daily volume of 902,920 shares. The stock had previously closed at C$35.48.

Separately, Fundamental Research cut their price target on shares of Halozyme Therapeutics from C$0.15 to C$0.12 and set a “buy” rating on the stock in a research note on Monday, September 27th.

The stock has a market capitalization of C$5.01 billion and a price-to-earnings ratio of 12.79. The company has a current ratio of 8.99, a quick ratio of 8.20 and a debt-to-equity ratio of 312.11. The firm has a 50-day moving average of C$36.82 and a 200-day moving average of C$40.27.

Halozyme Therapeutics (NEO:HALO) last announced its quarterly earnings data on Tuesday, November 2nd. The company reported C$0.52 earnings per share for the quarter, beating analysts’ consensus estimates of C$0.38 by C$0.14. The firm had revenue of C$115.83 million during the quarter, compared to analyst estimates of C$101.94 million. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 2.68 EPS for the current year.

Halozyme Therapeutics Company Profile (NEO:HALO)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.